Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Adherence to rationally prescribed medications is essential for effective pharmacotherapy. However, widely variable adherence to protocol-specified dosing regimens is prevalent among participants in ambulatory drug trials, mostly manifested in the form of underdosing. Drug actions are inherently dose and time dependent, and as a result, variable underdosing diminishes the actions of trial medications by various degrees. The ensuing combination of increased variability and decreased magnitude of trial drug actions reduces statistical power to discern between-group differences in drug actions. Variable underdosing has many adverse consequences, some of which can be mitigated by the combination of reliable measurements of ambulatory patients' adherence to trial and nontrial medications, measurement-guided management of adherence, statistically and pharmacometrically sound analyses, and modifications in trial design. Although nonadherence is prevalent across all therapeutic areas in which the patients are responsible for treatment administration, the significance of the adverse consequences depends on the characteristics of both the disease and the medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
A new taxonomy for describing and defining adherence to medications
Vrijens, B., De Geest, S., Hughes, D. A., Przemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04167.x · Cited by 2,028
Self-citationAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Farmer, K. C. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80026-5 · Cited by 889
Patient non-compliance with paper diaries
Stone, A. A., Shiffman, S., Schwartz, J. E., Broderick, J. E., & Hufford, M. R. (2002) · BMJ · doi:10.1136/bmj.324.7347.1193 · Cited by 810
Garber, M. C., Nau, D. P., Erickson, S. R., Aikens, J. E., & Lawrence, J. B. (2004) · Medical Care · doi:10.1097/01.mlr.0000129496.05898.02 · Cited by 519
Research works printed but not linked: 53
- Harter J.G., 1991, Ann. N. Y. Acad. Sci, 618, 563, 10.1111/j.1749-6632.1991.tb27276.x · doi:10.1111/j.1749-6632.1991.tb27276.x
- Blaschke T.F., 2012, Annu. Rev. Pharmacol. Toxicol, 52, 275, 10.1146/annurev-pharmtox-011711-113247 · DOI · Paper page
- Czobor P., 2011, Mol. Interv, 11, 107, 10.1124/mi.11.2.8 · DOI · Paper page
- Vrijens B., 2008, BMJ, 336, 1114, 10.1136/bmj.39553.670231.25 · DOI · Paper page
- Sheiner L.B., 1995, Clin. Pharmacol. Ther, 57, 6, 10.1016/0009-9236(95)90260-0 · DOI · Paper page
- Cross J., 2002, Pharmacoepidemiol. Drug Saf, 11, 439, 10.1002/pds.744 · DOI
- Heerdink E.R., 2002, Pharmacoepidemiol. Drug Saf, 11, 447, 10.1002/pds.745 · DOI
- Kaitin K.I., 2010, Pharm. Outsourcing, 11, 28, 30,
- Kaitin K.I., 2011, Clin. Pharmacol. Ther, 89, 183, 10.1038/clpt.2010.286 · DOI · Paper page
- Kaitin K.I., 2008, Clin. Pharmacol. Ther, 83, 210, 10.1038/sj.clpt.6100462 · DOI
- Kaitin K.I., 2010, Clin. Pharmacol. Ther, 87, 356, 10.1038/clpt.2009.293 · DOI · Paper page
- Munos B., 2009, Nat. Rev. Drug Discov, 8, 959, 10.1038/nrd2961 · DOI · Paper page
- DiMasi J.A., 2010, Clin. Pharmacol. Ther, 87, 272, 10.1038/clpt.2009.295 · DOI · Paper page
- Djulbegovic B., 2014, JAMA, 311, 355, 10.1001/jama.2013.283742 · DOI
- Sacks L.V., 2014, JAMA, 311, 378, 10.1001/jama.2013.282542 · DOI · Paper page
- 2011, Morb. Mortal. Wkly. Rep, 60, 1153
- Pullar T., 1989, Clin. Pharmacol. Ther, 46, 163, 10.1038/clpt.1989.121 · DOI · Paper page
- Rudd P., 1989, Clin. Pharmacol. Ther, 46, 169, 10.1038/clpt.1989.122 · DOI · Paper page
- Matsui D., 1994, J. Clin. Pharmacol, 34, 944, 10.1002/j.1552-4604.1994.tb04009.x · DOI · Paper page
- Arnsten J.H., 2001, Clin. Infect. Dis, 33, 1417, 10.1086/323201 · DOI · Paper page
- Carroll C.L., 2004, J. Am. Acad. Dermatol, 51, 212, 10.1016/j.jaad.2004.01.052 · DOI · Paper page
- Vrijens B., 2005, Basic Clin. Pharmacol. Toxicol, 96, 225, 10.1111/j.1742-7843.2005.pto960312.x · doi:10.1111/j.1742-7843.2005.pto960312.x
- Halpern M.T., 2006, Hypertension, 47, 1039, 10.1161/01.HYP.0000222373.59104.3d · DOI · Paper page
- Vrijens B., 2005, J. Clin. Pharmacol, 45, 461, 10.1177/0091270004274433 · DOI · Paper page
- Liu H., 2001, Ann. Intern. Med, 134, 968, 10.7326/0003-4819-134-10-200105150-00011 · DOI · Paper page
- Averbuch M., 1990, J. Clin. Res. Pharmacoepidemiol, 4, 199
- Rubio A., 1992, Clin. Pharmacokinet, 22, 238, 10.2165/00003088-199222030-00006 · DOI
- Girard P., 1996, J. Pharmacokinet. Biopharm, 24, 265, 10.1007/BF02353671 · DOI
- Vrijens B., 1999, Stat. Methods Med. Res, 8, 247, 10.1191/096228099669221405 · DOI
- Savic R.M., 2012, Clin. Pharmacol. Ther, 92, 575, 10.1038/clpt.2012.137 · DOI
- Burnier M., 2001, J. Hypertens, 19, 335, 10.1097/00004872-200102000-00022 · DOI · Paper page
- Marin D., 2010, J. Clin. Oncol, 28, 2381, 10.1200/JCO.2009.26.3087 · DOI · Paper page
- Rosen M.I., 2004, Behav. Res. Ther, 42, 409, 10.1016/S0005-7967(03)00149-9 · DOI
- Cramer J.A., 1999, J. Nerv. Ment. Dis, 187, 53, 10.1097/00005053-199901000-00009 · DOI · Paper page
- Demonceau J., 2013, Drugs, 73, 545, 10.1007/s40265-013-0041-3 · DOI · Paper page
- Sommer A., 1991, Stat. Med, 10, 45, 10.1002/sim.4780100110 · DOI · Paper page
- Efron B., 1991, J. Amer. Statist. Assoc, 86, 9, 10.1080/01621459.1991.10474996 · DOI · Paper page
- Kruse W., 1990, Eur. J. Clin. Pharmacol, 38, 561, 10.1007/BF00278582 · DOI
- Urquhart J., 1994, Clin. Pharmacokinet, 27, 202, 10.2165/00003088-199427030-00004 · DOI · Paper page
- Urquhart J., 1998, Adv. Drug Deliv. Rev, 33, 207, 10.1016/S0169-409X(98)00029-5 · DOI
- Paterson D.L., 2000, Ann. Intern. Med, 133, 21, 10.7326/0003-4819-133-1-200007040-00004 · DOI · Paper page
- Bangsberg D.R., 2001, AIDS, 15, 1181, 10.1097/00002030-200106150-00015 · DOI · Paper page
- Lowy A., 2011, Int. J. Clin. Pract, 65, 41, 10.1111/j.1742-1241.2010.02569.x · DOI · Paper page
- Vrijens B., 2004, Stat. Med, 23, 531, 10.1002/sim.1619 · DOI
- Comté L., 2009, Clin. Trials, 6, 403, 10.1177/1740774509344777 · DOI
- Fischer K., 2011, Biostatistics, 12, 247, 10.1093/biostatistics/kxq053 · DOI
- Vrijens B., 2005, Stat. Med, 24, 2719, 10.1002/sim.2130 · DOI
- Osterberg L.G., 2010, Clin. Pharmacol. Ther, 88, 457, 10.1038/clpt.2010.171 · DOI · Paper page
- Comté L, 2007, J Pharmacokinet Pharmacodyn, 34, 549, 10.1007/s10928-007-9058-0 · DOI
- Van Damme L., 2012, N. Engl. J. Med, 367, 411, 10.1056/NEJMoa1202614 · DOI · Paper page
- Baeten J., 2012, Curr. Opin. HIV AIDS, 7, 514, 10.1097/COH.0b013e3283582d30 · DOI
- Haberer J.E., 2013, PLoS Med, 10, e1001511, 10.1371/journal.pmed.1001511 · DOI · Paper page
- Karim S.S., 2011, Lancet, 378, e23, 10.1016/S0140-6736(11)61136-7 · DOI
Cited by
Adherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
Current Situation of Medication Adherence in Hypertension
Vrijens, B., Antoniou, S., Burnier, M., de la Sierra, A., & Volpe, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00100 · Cited by 292
Self-citationSPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials
Hróbjartsson, A., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081660 · Cited by 171
Mitigating the Effects of Nonadherence in Clinical Trials
Shiovitz, T. M., Bain, E. E., McCann, D. J., Skolnick, P., Laughren, T., Hanina, A., & Burch, D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.689 · Cited by 114
Medication adherence feedback with older adults with cognitive impairment: A mixed methods study
Sullivan, K. L., Hallowell, E. S., Goldstein, A., Commissariat, P. V., Daiello, L. A., Davis, J. D., & Margolis, S. A. (2025) · The Clinical Neuropsychologist · doi:10.1080/13854046.2024.2447094 · Cited by 4
Metadata
- Authors
- Vrijens, B., & Urquhart, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-03-12
- Volume
- 95
- Issue
- 6
- Pages
- 617-626
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2132001513
- Cited by
- 139
- References
- 13
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials. https://app.cochat.ai/papers/10.1038/clpt.2014.59
- The paper
- Vrijens, B., & Urquhart, J. (2014). Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2014.59
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.